By Will Feuer
Moderna backed its Covid-19 vaccine sales outlook for the year, saying the guidance already accounts for the uncertainty of U.S. vaccination rates.
The company said it “remains comfortable” with the outlook for 2023 Covid vaccine sales of $6 billion to $8 billion. The outlook was provided on Aug. 3.
If 50 million Covid vaccine doses are administered in the U.S., Moderna expects sales to be in the bottom half of its range. If 100 million doses are administered in the U.S., Moderna expects to be in the top half of the range.
The company said it will likely have a better idea of uptake after seeing full vaccination trends through October.
The Moderna disclosure comes after Pfizer said late Friday it was cutting its 2023 revenue guidance range by $9 billion, due to declines in expected sales of its Covid-19 vaccine Comirnaty and treatment Paxlovid.
Write to Will Feuer at Will.Feuer@wsj.com
Read the full article here
